Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology-focused biopharmaceutical company, has announced its upcoming participation in the Guggenheim Securities SMID Cap Biotech Conference in New York City. The company, which specializes in developing proprietary antibody-based therapeutics, will deliver a corporate presentation on Thursday, February 6, 2025, from 9:00-9:25 AM EST.
The presentation will be accessible via webcast, and a replay will remain available for 90 days on Compass' Events page. This conference, scheduled for February 5-6, 2025, provides an opportunity for Compass to showcase its developments in treating multiple human diseases.
Compass Therapeutics (Nasdaq: CMPX), un'azienda biofarmaceutica focalizzata sull'oncologia e in fase clinica, ha annunciato la sua prossima partecipazione alla Guggenheim Securities SMID Cap Biotech Conference a New York City. L'azienda, specializzata nello sviluppo di terapie a base di anticorpi proprietari, presenterà un intervento aziendale giovedì 6 febbraio 2025, dalle 9:00 alle 9:25 AM EST.
La presentazione sarà accessibile tramite webcast e una registrazione rimarrà disponibile per 90 giorni sulla pagina Eventi di Compass. Questa conferenza, in programma per il 5-6 febbraio 2025, offre a Compass l'opportunità di mostrare i suoi sviluppi nel trattamento di diverse malattie umane.
Compass Therapeutics (Nasdaq: CMPX), una compañía biofarmacéutica centrada en oncología y en fase clínica, ha anunciado su próxima participación en la Guggenheim Securities SMID Cap Biotech Conference en la ciudad de Nueva York. La empresa, que se especializa en desarrollar terapias basadas en anticuerpos propietarias, realizará una presentación corporativa el jueves 6 de febrero de 2025, de 9:00 a 9:25 AM EST.
La presentación será accesible a través de una transmisión en línea, y una repetición estará disponible durante 90 días en la página de Eventos de Compass. Esta conferencia, programada para el 5 y 6 de febrero de 2025, ofrece a Compass la oportunidad de mostrar sus desarrollos en el tratamiento de múltiples enfermedades humanas.
Compass Therapeutics (Nasdaq: CMPX), 임상 단계의 종양학 전문 생명공학 회사는 뉴욕시에서 열리는 Guggenheim Securities SMID Cap Biotech Conference에 참여할 예정이라고 발표했습니다. 항체 기반의 독자적인 치료제를 개발하는 전문 회사인 Compass는 2025년 2월 6일 목요일, 오전 9:00~9:25 (EST)에 기업 발표를 진행할 예정입니다.
이 발표는 웹캐스트를 통해 접속할 수 있으며, Compass의 이벤트 페이지에서 90일 동안 다시 시청할 수 있습니다. 2025년 2월 5일과 6일에 예정된 이 회의는 Compass가 여러 인간 질병에 대한 치료 개발을 선보일 수 있는 기회를 제공합니다.
Compass Therapeutics (Nasdaq: CMPX), une entreprise biopharmaceutique axée sur l'oncologie et en phase clinique, a annoncé sa prochaine participation à la Guggenheim Securities SMID Cap Biotech Conference à New York. L'entreprise, spécialisée dans le développement de thérapeutiques basées sur des anticorps propriétaires, fera une présentation d'entreprise le jeudi 6 février 2025, de 9h00 à 9h25 EST.
La présentation sera accessible via un webinaire, et une rediffusion sera disponible pendant 90 jours sur la page Événements de Compass. Cette conférence, prévue pour les 5 et 6 février 2025, offre à Compass l'occasion de présenter ses avancées dans le traitement de plusieurs maladies humaines.
Compass Therapeutics (Nasdaq: CMPX), ein biopharmazeutisches Unternehmen im klinischen Stadium mit Schwerpunkt auf Onkologie, hat seine bevorstehende Teilnahme an der Guggenheim Securities SMID Cap Biotech Conference in New York City angekündigt. Das Unternehmen, das sich auf die Entwicklung proprietärer, antikörperbasierter Therapeutika spezialisiert hat, wird am Donnerstag, den 6. Februar 2025, von 9:00 bis 9:25 Uhr EST eine Unternehmenspräsentation halten.
Die Präsentation wird über einen Webcast zugänglich sein, und eine Wiederholung wird für 90 Tage auf der Eventseite von Compass verfügbar sein. Diese Konferenz, die für den 5. und 6. Februar 2025 geplant ist, bietet Compass die Gelegenheit, seine Fortschritte bei der Behandlung verschiedener menschlicher Krankheiten vorzustellen.
- None.
- None.
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Guggenheim Securities SMID Cap Biotech Conference taking place in New York City, NY February 5-6, 2025.
Presentation Details
Date: Thursday, February 6, 2025
Time: 9:00-9:25 AM EST
Webcast Link: https://wsw.com/webcast/guggen2/cmpx
Virtual/Replay availability: The corporate presentation will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Chief of Staff
media@compasstherapeutics.com
617-500-8099
FAQ
When is Compass Therapeutics (CMPX) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How long will the CMPX Guggenheim Conference presentation replay be available?
Where can investors watch Compass Therapeutics' (CMPX) Guggenheim Conference presentation?
What type of therapeutics is CMPX developing as presented at the Guggenheim Conference?
